Interim report for the fourth quarter and full year 2013
March 3, 2014
FOURTH QUARTER HIGHLIGHTS
Continued progress on the start-up of NormoCort™ Phase 3 development – the first patient expected to be enrolled within the next few months
Acquired remaining shares in BioPancreate Inc. – holding the rights to a potential break-through treatment concept for Diabetes type 1 and 2
Net loss for the Group was SEK 10.3 million for the fourth quarter and SEK 32.9 million for the full year, compared with a net loss of SEK 8.1 million in the fourth quarter 2012 and SEK 23.7 million for the full year 2012
The cost level in the fourth quarter reflects higher G&A and other operating costs related to the preparations for a public exchange listing, as well as unrealized currency losses due to a generally weaker NOK
Liquid assets amounted to SEK 97.1 million at the end of 2013, up from SEK 24.3 million at the end of 2012
For the full report see attached pdf-file.
E-mail: [email protected]
Web: www.cortendo.com